
Turning Point Therapeutics TPTX
Quartalsbericht 2022-Q2
hinzugefügt 08.08.2022
Turning Point Therapeutics Langfristiger Schuldenstrom 2011-2026 | TPTX
Langfristiger Schuldenstrom Jährlich Turning Point Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.63 M | 1.4 M | 1.24 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.63 M | 1.24 M | 2.09 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Aquestive Therapeutics
AQST
|
510 K | $ 4.2 | 2.57 % | $ 364 M | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
argenx SE
ARGX
|
6.53 M | $ 832.2 | -0.96 % | $ 25 B | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 231.03 | -1.69 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.35 | 0.72 % | $ 8.06 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
BioVie
BIVI
|
74.5 K | $ 1.25 | 0.1 % | $ 1.85 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
BioMarin Pharmaceutical
BMRN
|
7.23 M | $ 61.64 | -1.57 % | $ 11.7 B | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Atea Pharmaceuticals
AVIR
|
800 K | $ 4.59 | -1.4 % | $ 387 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Capricor Therapeutics
CAPR
|
749 K | $ 28.36 | 1.61 % | $ 759 M | ||
|
CASI Pharmaceuticals
CASI
|
1.06 M | $ 0.36 | -54.61 % | $ 49 M | ||
|
Axsome Therapeutics
AXSM
|
434 K | $ 164.67 | -3.11 % | $ 8.19 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Catalyst Biosciences
CBIO
|
210 K | $ 12.11 | -4.27 % | $ 797 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
80.4 M | $ 190.86 | -2.19 % | $ 28 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | ||
|
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | ||
|
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Cellectis S.A.
CLLS
|
8.38 M | $ 4.17 | 4.77 % | $ 116 M | ||
|
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
39.5 M | $ 111.05 | 0.14 % | $ 27.2 B |